Dual Therapeutics, a spin-out from University Hospitals of Cleveland, is raising $7.5m. According to an amended Form D filed with the US Securities and Exchange Commission, the company has secured $3,689,611, with $3,810,389 still remaining.
The company, which is developing therapeutics for prostate cancer, lung cancer and acute lymphoblastic leukaemia, is based at Harlem Biospace in New York City, a life science incubator opened last year.
Dual’s technology is based on cancer research from the Icahn School of Medicine at…
